pembrolizumab yielded durable responses in patients with advanced merkel cell carcinoma
Published 8 years ago • 614 plays • Length 7:19Download video MP4
Download video MP3
Similar videos
-
2:18
durable responses to avelumab in patients with merkel cell carcinoma
-
4:25
new immunotherapy yields long-lasting responses in some patients with advanced m
-
4:31
treatment updates in merkel cell carcinoma
-
5:16
pembrolizumab found to be safe with durable responses in advanced, non-small cell lung cancer
-
5:58
pd-1 pathway blockade with pembrolizumab may effect frequent, durable responses in mcc patients
-
1:36
avelumab and pembrolizumab for the treatment of merkel cell carcinoma
-
1:06
managing avelumab side effects in patients with merkel cell carcinoma
-
2:19
chemotherapy vs. immunotherapy for the treatment of merkel cell carcinoma
-
5:55
targetting pd-l1 with avelumab in metastatic merkel cell carcinoma
-
1:37
dr. kaufman discusses durable responses to avelumab in merkel cell carcinoma
-
0:42
dr. kudchadkar on immunotherapy in merkel cell carcinoma
-
0:50
dr. nghiem on pembrolizumab for advanced merkel cell carcinoma
-
1:08
novel approaches in treating merkel cell carcinoma
-
2:26
nivolumab and ipilimumab in advanced merkel cell carcinoma
-
3:09
new insights in merkel cell biology and treatment
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
-
27:10
update in medical treatment of merkel cell carcinoma
-
1:43
dr. nghiem on immunotherapy in merkel cell carcinoma
-
1:18
dr. nghiem on challenges with immunotherapy in merkel cell carcinoma